| Objective and Background:Bladder uroepithelium cancer is the most common ma-lignant tumor of urology in China. The high recurrence and aggressive biological behavior indi-cate that there are still some mechanisms which can promote bladder uroepithelium cancer cells escaping the lethal effect immune cells. In this research, we detect the serum sMICA protein in healthy people and patients with bladder uroepithelium cancer, to valuate tumor escaping and the clinical application value of serum sMICA protein in patients with bladder uroepithelium cancer.Method:ELISA was used to detect the serum sMICA protein in thirty patients with bladder cancer excluded hepatitis, hyperpiesia, diabetes, rheumatism and rheumatoid disease and twenty healthy controls without organ affection including heart, lungs, liver and kidney, and without abnormalities of hepatic function and renal function, and without oncosis history of family.Results:sMICA was highly expressed on patients with bladder uroepithelium cancer. The level of serum sMICA in patients(57.808±20.706 ng/L) was higher significantly than that in con-trols(32.206±6.511 ng/L). In histopathology, the level of serum sMICA in patients with high grade uroepithelium cancer (76.660±28.386 ng/L) was higher significantly than that in patients with low grade uroepithelium cancer (49.723±8.421 ng/L). The level of serum sMICA in preop-erative patients(57.808±20.706 ng/L) was higher significantly than that in postoperative pa-tients(18.693±4.435 ng/L).Conclusion:The expression of serum sMICA protein in the patients with bladder cancer was significantly high. This may impair NKG2D-mediated immune surveillance of bladder uroepi-thelium cancer and lead to the tumor escaping. Serum sMICA protein could be considered as a new tumor symbol to evaluate the histopathology and the immunological function of patients with bladder uroepithelium cancer. The reverses and change of the tumor escaping may be a new biotherapy for bladder cancer. |
PDF Full Text Request